Linking Two Antimicrobial Peptides Together Keeps Bacteria-Killing Power While Reducing Toxicity

In vitro study synthesizing homo- and heterodimeric versions of a lipopeptide and a lactoferricin fragment linked by intermolecular disulfide bonds. Compounds were tested for antimicrobial activity against bacteria and fungi, and for hemolytic (red blood cell-destroying) activity as a measure of toxicity to human cells.

One of the biggest challenges in developing antimicrobial peptides as drugs is that many of them are toxic to human cells at the concentrations needed to kill bacteria. This study demonstrates a clever strategy — linking two different peptides via a disulfide bond — that preserves antibacterial punch while reducing collateral damage. If this approach generalizes, it could help solve the toxicity problem that has stalled many antimicrobial peptide drug candidates.

The antimicrobial resistance crisis demands new antibiotic approaches, and antimicrobial peptides are promising candidates — but toxicity has been a major hurdle. This study adds dimerization to the peptide chemist's toolkit for optimizing the balance between antimicrobial potency and safety. The approach could be applied to many other antimicrobial peptide pairs, potentially unlocking candidates that were previously too toxic for drug development.

This is an in vitro study with no animal or human data. The loss of antifungal activity limits the approach's versatility. Only a limited number of bacterial and fungal species were tested. The stability and pharmacokinetics of the disulfide-linked dimer in biological environments are unknown. Manufacturing complexity of dimeric peptides may be higher than monomers.